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LETTERS TO THE EDITOR
Clinical indications and proper use of
Visceral Adiposity Index
Visceral Adiposity Index (VAI), a gender-specific mathe-
matical index, based on simple anthropometric [BMI and
Waist Circumference (WC)] and metabolic parameters
[Triglycerides (TG) and HDL Cholesterol (HDL)], is a sur-
rogate marker of adipose tissue function and distribution,
independently correlated with insulin sensitivity and car-
diometabolic risk in the general population [1]. So far, VAI
is an empirical mathematical model that does not origi-
nate from theoretical assumptions, but from the obser-
vation in a healthy normal/overweight population of a
linear relationship between BMI and CV, from which a
linear equation has been extrapolated [1]. A Model of
Adipose Distribution (MOAD) was created based on this
linear equation and then it was corrected for TG and HDL,
determining the VAI.
In the last three years, it has been reported inmore than20
publications, in which there was evaluated the capability of
the VAI to express the cardiometabolic risk and a possible
“adipose tissue dysfunction”. The most important results
wereobtained inpopulations atmetabolic riskwithoutalways
having an overt Metabolic Syndrome (MetS) (general popula-
tion [1e4], women with PCOS [5,6], patients with NAFLD
[7e12], patients with HCV [13], patients with acromegaly
[14,15], patients with prolactinoma [16], patients with dia-
betes [17,18]). In some populations a specific cut-off was also
identified as able to facilitate the early recognition of car-
diometabolic risk in patients before they develop overt MetS.
Three of the variables making up the VAI (WC, TG, HDL)
being dichotomically expressed in the criteria of MetS, it is
also obvious that it is futile to apply the index in patients
with overt MetS.
However, certain studies in the same type of patients
have yielded conflicting results, and in some cases the
Figure 1 Legend: Distribution of the Visceral Adiposity Index (VAI) (A) and its component variables [BMI (B), Waist Circumfer-
ences (C), Triglycerides (D), HDL Cholesterol (E)] in a population of 1764 Primary Care patients.
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predictive power of the VAI has been ascribed to the indi-
vidual variables in the model (BMI, WC, TG, HDL). We think
these discrepancies can be attributed to the extreme vari-
ability of some variables in the model (e.g. TG) and to the
difficulties of WC assessment in morbid obesity and/or
pendulous abdomen. In order to investigate the variability of
the VAI and that of its components (BMI, WC, TG, HDL), in
the 1764 Primary Care patients studied in a previous study,
we retrospectively and cross-sectionally re-examined all
data [2]. Although among all the variables examined none
showed normal distribution (KolmogoroveSmirnov test:
p < 0.001 for all variables), VAI and TG show a greater
skewness (VAI: 3.00  0.05; BMI: 1.53  0.05; WC:
1.15  0.05; HDL: 0.58  0.05; TG: 2.57  0.05) and kurtosis
(VAI: 15.50  0.11; BMI: 2.90  0.11; WC: 2.03  0.11; HDL:
1.43  0.11; TG: 11.30  0.11) (Fig. 1): the two statistical
measures describe the lack of symmetry and the “peaked-
ness” of the curve of distribution, respectively. Therefore,
particularly high values of TG [values > 3.15 mmol/l or
279 mg/dl (values equal to the meanþ3SD in the 1764
Primary care patients studied)] could affect the validity of
VAI. In conclusion, for proper application in an individual
patient or in small sample size studies, the application of
the VAI is not recommended, in the presence of morbid
obesity, pendulous abdomen, severe hypertriglyceridemia
and/or or use of fibrates.
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